New Target for Triple-Negative Breast Cancer Identified

by Dr. Trupti Shirole on  February 8, 2015 at 5:07 PM Cancer News   - G J E 4
A new study by UT Southwestern Medical Center scientists has linked deficiency in a gene that controls autophagy, a process that recycles cell waste, with the triple-negative breast cancer.
 New Target for Triple-Negative Breast Cancer Identified
New Target for Triple-Negative Breast Cancer Identified

The scientists found based on analysis of two large breast cancer databases, reduced activity of an autophagy gene, beclin 1, was related to both a higher incidence of triple-negative breast cancer and a poorer prognosis for breast cancer patients. Dr. Beth Levine, Director of the Center for Autophagy Research, said, "With low beclin 1 expression, you have up to a 35-fold higher risk of having triple-negative breast cancer."

Low levels of beclin 1 activity was also correlated with worse outcomes. Thus increasing beclin 1 activity could become a new therapy for breast cancer patients, especially those with the triple-negative type. Several approved drugs that happen to increase beclin 1 activity are already in use for other types of cancer. They include four classes of drugs- inhibitors of either beclin 1/BCL-2 binding, protein kinase B (AKT), epidermal growth factor receptor (EGFR), or HER2.

The study appears in the online journal EBioMedicine.

Source: Medindia

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like